ArticleOpen forum infectious diseases2016
Nocardiosis in the Tropical Northern Territory of Australia, 1997-2014.
Article in Open forum infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- Research progress on clinical challenges and prevention strategies of drug-resistantFrontiers in public health · 2026Review
- Genomic characteristics, virulence potential, antimicrobial resistance profiles, and phylogenetic insights into Nocardia cyriacigeorgica.Annals of clinical microbiology and antimicrobials · 2025Article
- The genus Nocardia as a source of new antimicrobials.npj antimicrobials and resistance · 2025Review
- Metagenomic analysis identifying a polymicrobial pulmonary infection in a non-HIV immunocompromised patient: a case report.BMC pulmonary medicine · 2025Article
- Article
- First Documented Case of Pneumonia withInfection and drug resistance · 2025Article
- Severe pneumonia caused byFrontiers in medicine · 2025Article
- Epidemiology ofAntibiotics (Basel, Switzerland) · 2022Article
- Nocardiosis in Japan: a Multicentric Retrospective Cohort Study.Antimicrobial agents and chemotherapy · 2022Article
- Estradiol AggravateFrontiers in immunology · 2022Article
- Misdiagnosed tuberculosis being corrected as Nocardia farcinica infection by metagenomic sequencing: a case report.BMC infectious diseases · 2021Article
- Insights from the comparative genome analysis of natural rubber degradingBioinformation · 2021Article
- Membranous Nephropathy Complicated with DisseminatedInfection and drug resistance · 2021Article
- Efficient differentiation ofJournal of medical microbiology · 2020Article
- Clinical Nocardia species: Identification, clinical characteristics, and antimicrobial susceptibility in Shandong, China.Bosnian journal of basic medical sciences · 2020Article
- Safety and Outcomes of Linezolid Use for Nocardiosis.Open forum infectious diseases · 2020Article
- Orbital and intracranial Nocardia farcinica infection caused by trauma to the orbit: a case report.BMC infectious diseases · 2019Article
- Updates on Nocardia Skin and Soft Tissue Infections in Solid Organ Transplantation.Current infectious disease reports · 2019Review
- Manifestations and outcomes of nocardia infections: Comparison of immunocompromised and nonimmunocompromised adult patients.Medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
background
methodsWe conducted a retrospective cohort study of nocardiosis diagnosed between 1997 and 2014. Population-based incidences were calculated using district population data.
resultsClinically significant nocardiosis was identified in 61 patients. The unadjusted population-based annual incidence of nocardiosis was 2.02 (95% confidence interval [CI], 1.55-2.60) per 100000 people and was 1.7 (95% CI, .96-2.90) fold higher in Indigenous compared with non-Indigenous persons (
conclusionsThe incidence of nocardiosis in tropical Australia is amongst the highest reported globally. Nocardiosis occurs in both immunocompromised and immunocompetent hosts, and it is associated with high rates of ICU admission, 1-year mortality, and resistance to commonly recommended antimicrobials. Diagnosis should be considered in patients with consistent clinical features, particularly if they are Indigenous or have chronic lung disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.